SCHEMBL4740259

SCHEMBL4740259

Nc1onc2c(OCCN3CCOCC3)ccc(-c3ccc(NC(=O)Nc4cccc(C(F)(F)F)c4)cc3)c12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 8/20 0.59
FLT3 P36888 8/20 0.59
KIT P10721 6/20 0.59
PDGFRB P09619 2/20 0.56
CSF1R P07333 2/20 0.56
FLT1 P17948 2/20 0.56
TEK Q02763 1/20 0.56
HTR2A P28223 6/20 0.55
HTR2C P28335 5/20 0.55
EPHX2 P34913 3/20 0.55
KCNH2 Q12809 1/20 0.53
RXFP1 Q9HBX9 1/20 0.52
IKBKE Q14164 1/20 0.52
ABL1 P00519 1/20 0.50
LCK P06239 1/20 0.50
FYN P06241 1/20 0.50
LYN P07948 1/20 0.50
SRC P12931 1/20 0.50
FLT4 P35916 1/20 0.50
BLK P51451 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL421068 0.90 KDR (0.69) KDRFLT3KITPDGFRBCSF1R
SCHEMBL4739871 0.89 KDR (0.67) KDRFLT3KITPDGFRBCSF1R
SCHEMBL1382868 0.89 KDR (0.74) KDRFLT3KITPDGFRBCSF1R
SCHEMBL4736503 0.86 IKBKE (0.65) KDRFLT3KITPDGFRBCSF1R
SCHEMBL423540 0.85 KDR (0.80) KDRFLT3KITPDGFRBCSF1R
SCHEMBL5249636 0.82 KDR (0.67) KDRFLT3KITPDGFRBCSF1R
SCHEMBL4735702 0.82 KDR (0.78) KDRFLT3KITPDGFRBCSF1R
SCHEMBL422682 0.82 KDR (0.74) KDRFLT3KITPDGFRBCSF1R
SCHEMBL4735874 0.82 KDR (0.82) KDRFLT3KITPDGFRBCSF1R
SCHEMBL1384424 0.82 KDR (0.73) KDRFLT3KITPDGFRBCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed